Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease
NCT06679140 · View on ClinicalTrials.gov ↗
Study Summary
The purpose of the study is to evaluate whether ibuzatrelvir is effective and safe in adults and adolescents with COVID-19 who do not need to be in the hospital but who are at high risk for progression to severe disease. Eligible participants will be randomly assigned (by chance) to receive ibuzatrelvir or matching placebo orally for 5 days. Co-administration of locally available standard of care is allowed. The total duration of the study is around 6 months.
Conditions Studied
Interventions
- DRUG placebo
- DRUG ibuzatrelvir
Study Locations (20)
California
- National Institute of Clinical Research - Bakersfield — Bakersfield
- 310 Clinical Research — Inglewood
- Long Beach Research Institute — Long Beach
- Long Beach Clinical Trials — Long Beach
- Downtown L.A. Research Center, Inc. — Los Angeles
- Clinica mi Salud by Focil Med — Oxnard
- FOMAT Medical Research — Oxnard
- Paradigm Clinical Research, LLC — Redding
- Acclaim Clinical Research — San Diego
- Tweedy Medical Group - Charity Health — South Gate
- Breathe Clear Institute for Sinus and Allergy Relief — Torrance
Florida
- Innovative Research of West Florida — Clearwater
- Invictus Clinical Research Group — Coconut Creek
- Hillcrest Medical Research LLC — DeLand
- Hillcrest Medical Research — DeLand
- Universal Axon Clinical Research, LLC — Doral
District of Columbia
- Georgetown University Medical Center — Washington D.C.
- Emerson Clinical Research Institute — Washington D.C.
Arkansas
- Applied Research Center of Arkansas — Little Rock
Colorado
- Paradigm Clinical Research, LLC — Wheat Ridge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,330 participants |
| Start Date | 2024-12-08 |
| Est. Completion | 2028-03-02 |
| Phase | Phase 3 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06679140
The ClinicalTrials.gov registry entry for NCT06679140 describes a study currently listed as recruiting. It is categorized as Phase 3, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 2,330 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 769 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with COVID-19 SARS-CoV-2 Infection appearing as the primary indexed condition, and to 2 interventions — of which placebo is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT06679140 reports 20 study locations spanning 5 distinct geographic areas — top geographies include California, Florida, District of Columbia. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT06679140 about?
NCT06679140 is a clinical study titled "A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease". The purpose of the study is to evaluate whether ibuzatrelvir is effective and safe in adults and adolescents with COVID-19 who do not need to be in the hospital but who are at high risk for progression to severe disease. Eligible participants will be randomly assigned (by chance) to receive ibuzatre...
What is the current status of trial NCT06679140?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 2,330 participants. The study started on 2024-12-08. Estimated completion is 2028-03-02.
What conditions does trial NCT06679140 study?
This clinical trial studies the following conditions: COVID-19 SARS-CoV-2 Infection. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT06679140?
The interventions under investigation include: placebo (DRUG), ibuzatrelvir (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT06679140?
This trial is sponsored by Pfizer, which has 769 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT06679140 being conducted?
This trial has 20 study locations across Arkansas, California, Colorado, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.